2014
June 18, 2014
Genelex, a pioneer in pharmacogenetic testing, analysis and comprehensive medication management software that helps medical professionals understand the interaction between a patient’s genetics and their entire drug regimen, announces its selection as one of the top 100 mid-sized companies to work for in Seattle, for the third consecutive year.
Seattle Business magazine’s annual award is based primarily on anonymous input from employees; winners are then selected from a panel of distinguished local business leaders. Employees are surveyed about what makes them happy with their work – on topics from company leadership, benefits, work environment, and innovation in training programs. The awards were presented Tuesday evening at the magazine’s Award Gala.
Founded in 1987, Genelex has been on a fast-track trajectory of growth since it began focusing on pharmacogenetic testing (also known as drug sensitivity testing) in 2000. The company’s mission, “science that benefits humanity,” as well as its people-first, entrepreneurial environment make it a highly attractive employer.
“We’ve grown from a small, family-owned company to now employing more than 100 people,” says Howard Coleman, Genelex co-founder and CEO. “It’s gratifying to see our caring company culture and commitment to quality continue while growing at such a high rate. It’s exciting to meet and hire the young professionals motivated by our culture and potential, as we continue to make advances that have a real positive impact on healthcare.”
According to Seattle Business magazine, a record number of companies large and small from all over the state entered this competition. “To make the list this year especially, when so many did not, is a powerful statement about how winning companies treat their people,” notes Michael Romoser, associate publisher of Seattle Business.
To learn more about Genelex and current employment opportunities, please visit www.genelex.jp.
Genelex, a pioneer in pharmacogenetic testing, analysis and comprehensive medication management software that helps medical professionals understand the interaction between a patient’s genetics and their entire drug regimen, announces its selection as one of the top 100 mid-sized companies to work for in Seattle, for the third consecutive year.
Seattle Business magazine’s annual award is based primarily on anonymous input from employees; winners are then selected from a panel of distinguished local business leaders. Employees are surveyed about what makes them happy with their work – on topics from company leadership, benefits, work environment, and innovation in training programs. The awards were presented Tuesday evening at the magazine’s Award Gala.
Founded in 1987, Genelex has been on a fast-track trajectory of growth since it began focusing on pharmacogenetic testing (also known as drug sensitivity testing) in 2000. The company’s mission, “science that benefits humanity,” as well as its people-first, entrepreneurial environment make it a highly attractive employer.
“We’ve grown from a small, family-owned company to now employing more than 100 people,” says Howard Coleman, Genelex co-founder and CEO. “It’s gratifying to see our caring company culture and commitment to quality continue while growing at such a high rate. It’s exciting to meet and hire the young professionals motivated by our culture and potential, as we continue to make advances that have a real positive impact on healthcare.”
According to Seattle Business magazine, a record number of companies large and small from all over the state entered this competition. “To make the list this year especially, when so many did not, is a powerful statement about how winning companies treat their people,” notes Michael Romoser, associate publisher of Seattle Business.
To learn more about Genelex and current employment opportunities, please visit www.genelex.jp.
# # #
About Genelex Genelex is a pioneer in comprehensive medication management, pharmacogenetic testing and analysis. Its patented YouScript® Personalized Prescribing System is the only medication management system to assess the cumulative effect of a patient’s genetics and entire drug regimen to help prevent unwanted side effects and treatment failures. YouScript was a finalist in the Allscripts Open App Challenge, and is used by healthcare providers, clinical researchers and managed and accountable care organizations. Founded in 1987, Genelex is based in Seattle and was one of the first labs to provide pharmacogenetic testing and interpretation. For more information, contact the company at 800.TEST.DNA or visit www.genelex.jp or www.youscript.com.2013
September 11, 2013
Puget Sound Business Journal After a record-breaking time of expansion, Genelex makes Puget Sound Business Journal's prestigious list of top 100 fastest-growing private companies in 2013. Read full article.
Puget Sound Business Journal After a record-breaking time of expansion, Genelex makes Puget Sound Business Journal's prestigious list of top 100 fastest-growing private companies in 2013. Read full article.
2012
September 12, 2012
Howard Coleman and Kristine Ashcraft talk to Jane Shannon, of KOMO News Radio, about the YouScript Personalized Prescribing System.
Howard Coleman and Kristine Ashcraft talk to Jane Shannon, of KOMO News Radio, about the YouScript Personalized Prescribing System.
September 12, 2012
KOMO - Molly Shen - A local company has a new approach to personalized medicine: getting your prescription drugs based on your DNA. Read the article and watch the TV spot.
KOMO - Molly Shen - A local company has a new approach to personalized medicine: getting your prescription drugs based on your DNA. Read the article and watch the TV spot.
August 1, 2012
Practical Pain Management Journal - Dr. Forest Tennant - Severe, chronic pain patients who seek opioid dosages above normal standards should now be tested for genetic cytochrome P450 deficiencies. - Available in the August 2012 issue. Subscription required.
Practical Pain Management Journal - Dr. Forest Tennant - Severe, chronic pain patients who seek opioid dosages above normal standards should now be tested for genetic cytochrome P450 deficiencies. - Available in the August 2012 issue. Subscription required.
July 1, 2012
Kalorama - The Worldwide Market for In Vitro Diagnostic Tests, is a testament to the Kalorama methodology. Real industry knowledge combined with an exhaustive review of the medical, business, and company literature. Market numbers for business planning matched with a discovery of the trends that are impacting the industry. A realistic forecast five years into the future for companies already participating in or considering entry into this growing industry.
Kalorama - The Worldwide Market for In Vitro Diagnostic Tests, is a testament to the Kalorama methodology. Real industry knowledge combined with an exhaustive review of the medical, business, and company literature. Market numbers for business planning matched with a discovery of the trends that are impacting the industry. A realistic forecast five years into the future for companies already participating in or considering entry into this growing industry.
June 1, 2012
Kalorama - In February and March of 2012, Kalorama Information conducted a survey of 2,000 adults to ask them whether or not they would take a genetic test. This report, Consumer Testing and the Future of DTC Genetic Testing provides those results and compiles surveys from public and private sources.
Kalorama - In February and March of 2012, Kalorama Information conducted a survey of 2,000 adults to ask them whether or not they would take a genetic test. This report, Consumer Testing and the Future of DTC Genetic Testing provides those results and compiles surveys from public and private sources.
March 1, 2012
Kalorama - In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to analysis of tests currently on the market and in development, the report profiles key competitors and discusses trends that are important for understanding this much-discussed growth area of the diagnostic industry.
Kalorama - In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to analysis of tests currently on the market and in development, the report profiles key competitors and discusses trends that are important for understanding this much-discussed growth area of the diagnostic industry.
2010
October 24, 2010
USA Today - Rita Rubin - Since the Human Genome Project was completed in 2003, the introduction of new genetic tests has far outpaced the ability of doctors — who typically have little training in genetics — to figure out what to do with them. Some tests are marketed to help predict disease risk, others to determine how patients might respond to certain medications.
USA Today - Rita Rubin - Since the Human Genome Project was completed in 2003, the introduction of new genetic tests has far outpaced the ability of doctors — who typically have little training in genetics — to figure out what to do with them. Some tests are marketed to help predict disease risk, others to determine how patients might respond to certain medications.
2009
October 9, 2009
Genome Web - Kirell Lakhman - Quest Diagnostics later this month plans to offer nationwide a PCR-based assay designed to predict response to the anticoagulant Plavix. According to genetic-testing company Genelex, which is among several shops offering similar assays, “most” of the approximately 1 million patients who undergo coronary stent procedures each year in the US are prescribed Plavix. Those that carry mutated versions of the CYP2C19 gene will not likely respond well to the drug, which puts them at greater risk for adverse cardio- and neurovascular events.
1
2
3
4
Next » Genome Web - Kirell Lakhman - Quest Diagnostics later this month plans to offer nationwide a PCR-based assay designed to predict response to the anticoagulant Plavix. According to genetic-testing company Genelex, which is among several shops offering similar assays, “most” of the approximately 1 million patients who undergo coronary stent procedures each year in the US are prescribed Plavix. Those that carry mutated versions of the CYP2C19 gene will not likely respond well to the drug, which puts them at greater risk for adverse cardio- and neurovascular events.
